
- BioPharm International-06-15-2016
- Volume 2016 ebook
- Issue 1
Regulatory Reform in China: Implications for Global Biopharmaceutical Companies
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.
Download the
.
Articles in this issue
over 9 years ago
Contract Service Providers Gear Up to Develop Emerging Therapiesover 9 years ago
Biopharma Service Providers Address a Full Plate of Challengesover 9 years ago
Dealing with Pharmaceutical Supply-Chain Complexitiesover 9 years ago
Keeping it Simple: Collaborating for Success in Drug Deliveryover 9 years ago
Biomanufacturers Demand Higher Quality Standards in 2016over 9 years ago
Preventing Phase III Failuresover 9 years ago
Outsourcing Industry Marked by Considerable Investments in 2016Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.